In the Cohort 2 analysis, 29 of 295 patients with EGFR-wild type lung adenocarcinoma (9.8%) were found to have EML4-ALK translocation and none of them harbored other driver gene mutations. Here, EML4 is linked to lung adenocarcinoma.